// App-Quantinova.ai

: Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Researchers

Presenter

  • Alan P. Skarbnik

Principal Investigators

  • Franklin L. Chen

  • Luke Mountjoy

  • Zaw Win Myint

  • Patricia A. Young

  • Andrew R. Whiteley

  • Steven Novick

  • Jennifer Su

  • Qingxi Wang

  • Kevin Romanko

  • Xi-De Wang

  • Yejia Li

  • Shulin Zhong

  • Liping Song

  • Ranjana H. Advani

Medical Centers

  • Novant Health Oncology Specialists, Winston-Salem, NC

  • Hematology Department, Colorado Blood Cancer Institute, Denver, CO

  • Lymphoma and CLL Program, Novant Health Cancer Institute, Charlotte, NC

  • Baylor University Medical Center, Dallas, TX

  • Department of Medicine, Division of Oncology, Stanford University, Stanford, CA

  • Division of Hematology, University of Southern California, Norris Comprehensive Cancer Center, Walnut, CA

  • CSPC, Shanghai, China

  • Conjupro Biotherapeutics, Princeton, NJ

  • Division of Hematology and Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA

Locations

  • United States

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • Bruton tyrosine kinase

  • B-lymphocyte antigen CD20

  • Cluster of Differentiation 47

  • Apparent diffusion coefficient

Drug/Treatment

  • thrombospondin-1

  • ofatumumab Intravenous

  • Rituximab

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Multicenteric

  • Tolerability

  • Expansion Study

  • Dose Escalation

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved